Boulevard Bio (Series A)
Funding Details
Awarder
Inbox
Date Award
August 12, 2026
Vertical
Biotechnology
Funding Amount
$65,000,000
Company Info
Founders
Pioneers in B cell biology
Market
B cell-driven autoimmune diseases
Location
New York, NY, USA
Coinvestors
Deerfield Management Company, L.P.
Company Description

Boulevard Bio is a precision immunology company built to change the course of B cell-driven autoimmune diseases with targeted, multi-specific medicines designed to set new therapeutic standards. Boulevard is advancing a pipeline of multi-specific antibodies grounded in a deep understanding of B cell disease biology to pair the right targets and modalities to the right disease across the spectrum of B cell-driven autoimmune conditions.

Links